Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Anti-inflammatory agents. --- Anti-inflammatories --- Antiinflammatory agents --- Antiphlogistics --- Antipyretics --- Inflammation

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Advances in Anti-inflammatory Therapy explores the cutting-edge in anti-inflammation therapy in clear and concise language, with insights from academia and industry. Sections cover key regulatory pathways that mediate acute and chronic inflammation and disease onset. Further chapters are devoted to advanced anti-inflammatory pharmaceuticals, including chemical moieties, pharmacophores, APIs, natural products, herbal therapies, molecular nanomedicine and advanced drug delivery vectors. Systematically planned chapters and illustrations enable potential readers to gain essential insights on the most recent advancements in the field. Arranged with systematic chapters covering a broad range of inflammatory diseases, discussions on past, current and future therapeutics and advanced anti-inflammatory pharmaceuticals, this book will be useful to a wide range of researchers, especially medicinal chemists, drug design experts, and biological and translational researchers working in the field of inflammation.

Anti-inflammatory agents. --- Anti-inflammatories --- Antiinflammatory agents --- Antiphlogistics --- Antipyretics --- Inflammation --- Anti-Inflammatory Agents --- Treatment. --- drug therapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pathology of the organs of movement --- Pharmacology. Therapy --- Infectious diseases. Communicable diseases --- Pharmacosynthesis. Pharmacochemistry --- Anti-inflammatory agents --- Antiinflammatoires --- #Lilly --- Anti-inflammatories --- Antiinflammatory agents --- Antiphlogistics --- Antipyretics --- Inflammation --- Anti-Inflammatory Agents.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

612.112 --- 577.27 --- 615.276 --- White blood corpuscles (leucocytes). Phagocytes. Amoeboid cells. White cell count, number, shapes. Lymphocytes. Monocytes --- Molecular bases of immunity. Molecular immunology --- Anti-inflammatory agents generally. Antiphlogistics --- Conferences - Meetings --- Interleukin-12 --- Congresses. --- immunology --- congresses. --- 615.276 Anti-inflammatory agents generally. Antiphlogistics --- 577.27 Molecular bases of immunity. Molecular immunology --- 612.112 White blood corpuscles (leucocytes). Phagocytes. Amoeboid cells. White cell count, number, shapes. Lymphocytes. Monocytes --- IL-12 (Biomolecule) --- Natural killer cell stimulatory factor --- Cytokines --- Interleukins --- Congresses --- Interleukin-12 - Congresses.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Over the last decade, the advent of biologic agents has greatly revolutionized therapeutic medicine in the management of chronic inflammatory diseases, such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Elucidation of the complex web of cytokine network and the roles of these cytokines in the pathogenesis of inflammatory disorders provided one of the key catalysts for the advancement of targeted biologic therapy in autoimmune and inflammatory diseases. TNF-alpha is known to play a crucial role in the pathogenesis of many chronic inflammatory diseases. Elevated levels of TNF-alpha have been demonstrated in Crohn’s disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, suggesting a role for TNF-alpha in their pathogenesis. Although TNF-alpha plays a critical role in the activation of innate and acquired immune responses, the persistence of the immune response and inappropriate production of TNF-alpha can produce pathological changes resulting from chronic inflammation and tissue damage. This volume provides a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-alpha inhibitors – etanercept, infliximab, and adalimumab. The most recent preclinical and clinical data is presented on this topic, which should be of interest to the preclinical researcher, the clinician, and the patient who wants to learn more about these therapies.

Tumor necrosis factor --- Anti-inflammatory agents. --- Inhibitors. --- Anti-inflammatories --- Antiinflammatory agents --- Antiphlogistics --- Antipyretics --- Inflammation --- Cachectin --- Lymphotoxin --- TNF (Immunology) --- Cytokines --- Glycoproteins --- Growth factors --- Macrophages --- Immunology. --- Rheumatology. --- Dermatology. --- Toxicology. --- Gastroenterology. --- Pharmacology/Toxicology. --- Internal medicine --- Digestive organs --- Chemicals --- Medicine --- Pharmacology --- Poisoning --- Poisons --- Skin --- Connective tissues --- Joints --- Immunobiology --- Life sciences --- Serology --- Diseases --- Toxicology --- Pharmacology. --- Gastroenterology . --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemotherapy --- Drugs --- Pharmacy --- Physiological effect